Levin AA[au] - Search Results

Year	Number of Results
1927	1
1970	1
1974	1
1977	1
1978	1
1980	2
1981	2
1982	2
1983	1
1984	3
1985	3
1986	2
1987	2
1988	2
1989	1
1991	2
1992	5
1994	3
1995	3
1996	7
1997	13
1998	3
1999	9
2000	2
2001	7
2002	5
2003	4
2004	6
2005	1
2006	6
2007	1
2008	3
2009	3
2011	1
2012	5
2013	4
2014	8
2015	4
2016	1
2017	1
2018	1
2019	2
2020	2
2021	2
2022	1

1

Treating Disease at the RNA Level with Oligonucleotides.

Levin AA. Levin AA. N Engl J Med. 2019 Jan 3;380(1):57-70. doi: 10.1056/NEJMra1705346. N Engl J Med. 2019. PMID: 30601736 Review. No abstract available.

2

Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study.

Täubel J, Hauke W, Rump S, Viereck J, Batkai S, Poetzsch J, Rode L, Weigt H, Genschel C, Lorch U, Theek C, Levin AA, Bauersachs J, Solomon SD, Thum T. Täubel J, et al. Among authors: levin aa. Eur Heart J. 2021 Jan 7;42(2):178-188. doi: 10.1093/eurheartj/ehaa898. Eur Heart J. 2021. PMID: 33245749 Free PMC article. Clinical Trial.

3

Developing microRNA therapeutics.

van Rooij E, Purcell AL, Levin AA. van Rooij E, et al. Among authors: levin aa. Circ Res. 2012 Feb 3;110(3):496-507. doi: 10.1161/CIRCRESAHA.111.247916. Circ Res. 2012. PMID: 22302756 Review.

4

Targeting Therapeutic Oligonucleotides.

Levin AA. Levin AA. N Engl J Med. 2017 Jan 5;376(1):86-88. doi: 10.1056/NEJMcibr1613559. N Engl J Med. 2017. PMID: 28052219 No abstract available.

5

Developing microRNA therapeutics: approaching the unique complexities.

Jackson AL, Levin AA. Jackson AL, et al. Among authors: levin aa. Nucleic Acid Ther. 2012 Aug;22(4):213-25. doi: 10.1089/nat.2012.0356. Nucleic Acid Ther. 2012. PMID: 22913594 Review.

6

Continuous versus intermittent therapy for moderate-to-severe psoriasis.

Ramirez-Fort MK, Levin AA, Au SC, Gottlieb AB. Ramirez-Fort MK, et al. Among authors: levin aa. Clin Exp Rheumatol. 2013 Jul-Aug;31(4 Suppl 78):S63-70. Epub 2013 Oct 4. Clin Exp Rheumatol. 2013. PMID: 24129141 Review.

7

Specific targeting of interleukin-23p19 as effective treatment for psoriasis.

Levin AA, Gottlieb AB. Levin AA, et al. J Am Acad Dermatol. 2014 Mar;70(3):555-61. doi: 10.1016/j.jaad.2013.10.043. Epub 2013 Dec 24. J Am Acad Dermatol. 2014. PMID: 24373779 Review.

8

Magnetic Patterning of Tissue Spheroids Using Polymer Microcapsules Containing Iron Oxide Nanoparticles.

Koudan EV, Zharkov MN, Gerasimov MV, Karshieva SS, Shirshova AD, Chrishtop VV, Kasyanov VA, Levin AA, Parfenov VA, Karalkin PA, Pereira FDAS, Petrov SV, Pyataev NA, Khesuani YD, Mironov VA, Sukhorukov GB. Koudan EV, et al. Among authors: levin aa. ACS Biomater Sci Eng. 2021 Nov 8;7(11):5206-5214. doi: 10.1021/acsbiomaterials.1c00805. Epub 2021 Oct 5. ACS Biomater Sci Eng. 2021. PMID: 34610738

9

The Oligonucleotide Safety Working Group (OSWG).

Schubert D, Levin AA, Kornbrust D, Berman CL, Cavagnaro J, Henry S, Seguin R, Ferrari N, Shrewsbury SB. Schubert D, et al. Among authors: levin aa. Nucleic Acid Ther. 2012 Aug;22(4):211-2. doi: 10.1089/nat.2012.0383. Nucleic Acid Ther. 2012. PMID: 22913593 No abstract available.

10

Synthetic oligonucleotides: the development of antisense therapeutics.

Monteith DK, Levin AA. Monteith DK, et al. Among authors: levin aa. Toxicol Pathol. 1999 Jan-Feb;27(1):8-13. doi: 10.1177/019262339902700103. Toxicol Pathol. 1999. PMID: 10367666 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results